Does Rallies show 13F holders for TOI?

Yes. Rallies tracks hedge fund and 13F ownership data for TOI, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TOI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TOI. It does not provide personalized investment advice.

TOI (The Oncology Institute, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

The Oncology Institute, Inc. Common Stock (TOI) is a publicly traded Healthcare sector company. As of May 21, 2026, TOI trades at $4.17 with a market cap of $399.93M and a P/E ratio of -11.64. TOI moved +2.32% today. Year to date, TOI is +7.14%; over the trailing twelve months it is +51.08%. Its 52-week range spans $0.13 to $4.88. Analyst consensus is strong buy with an average price target of $7.00. Rallies surfaces TOI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TOI stock?

Hedge funds tracked by Rallies that own TOI include Centerbook Partners, Panagora Asset, Mangrove Partners, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for The Oncology Institute, Inc. Common Stock.

TOI Key Metrics

Key financial metrics for TOI
Metric	Value
Price	$4.17
Market Cap	$399.93M
P/E Ratio	-11.64
EPS	$-0.35
Dividend Yield	0.00%
52-Week High	$4.88
52-Week Low	$0.13
Volume	1.27K
Avg Volume	0
Revenue (TTM)	$545.76M
Net Income	$-43.51M
Gross Margin	0.00%

Top Hedge Funds Holding TOI

Centerbook Partners holds 1.57M shares of TOI, changed -48.23% as of Mar 31, 2026.
Panagora Asset holds 126.98K shares of TOI, changed +0.00% as of Sep 30, 2025.
Mangrove Partners holds 30.58K shares of TOI, changed +0.00% as of Dec 31, 2025.
Pinebridge Investments holds 29.78K shares of TOI, changed +0.00% as of Sep 30, 2023.

Latest TOI News

Oncology Institute Guides Q1 Revenue $143.23M, Raises Full-Year Estimate to $647.84M — May 6, 2026
Oncology Institute Achieves First Profit, Grows Revenue 28% to $500M+ — Mar 13, 2026
Oncology Institute Forecasts Q4 Revenue $139.8M, EPS –$0.09; 2026 Revenue Raised — Mar 11, 2026

Recent TOI Insider Trades

Chernett Jorey bought 30.00K (~$122.70K) on May 19, 2026.
Kaushal Mohit sold 38.43K (~$134.53K) on Apr 16, 2026.
Kaushal Mohit sold 57.29K (~$200.60K) on Apr 14, 2026.

TOI Analyst Consensus

4 analysts cover TOI: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.00.

Common questions about TOI

Who owns TOI stock?: Hedge funds tracked by Rallies that own TOI include Centerbook Partners, Panagora Asset, Mangrove Partners, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for The Oncology Institute, Inc. Common Stock.
Does Rallies show 13F holders for TOI?: Yes. Rallies tracks hedge fund and 13F ownership data for TOI, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TOI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TOI. It does not provide personalized investment advice.